Ipamorelin results: what to expect and when

An experimental peptide that triggers growth hormone release.

Also called: NNC 26-0161, NNC-26-0161.

Growth hormone secretagogues (ghrelin receptor) · Ghrelin receptor agonist and growth hormone secretagogue.

A bowel-surgery trial used IV infusions twice daily for up to seven days or until discharge; this does not define a home-injection course.

Five human research records, two from registries only, plus two reports to FDA. The published bowel-surgery trial found no clear benefit; a review includes the same trial.

Key studies

  • First human IV dose study: IV ipamorelin produced a brief GH pulse; it did not test a chronic wellness regimen. (source)
  • Bowel surgery: 0.03 mg/kg: The main and secondary efficacy analyses did not show a significant benefit. (source)
  • Second bowel-surgery trial: A larger completed dose-finding trial remains a major unpublished-results gap. (source)
  • Nasal exposure for doping analysis: This documents human nasal exposure, not a clinical-use schedule. (source)
  • Veterans: mixed-treatment cohort: A registered mixed-treatment cohort provides no isolated ipamorelin outcome evidence. (source)
  • Nasal headache report: Headache and watery eyes; product quality was questioned. (source)

Related to Ipamorelin

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.